See Also: See also Anthelmintics.
Action/Kinetics: Acts by inhibiting tubular polymerization, resulting in the loss of cytoplasmic microtubules and inability of the cell to function. Poorly absorbed from the GI tract; enhance absorption by ingesting a meal containing at least 40 g of fat. Rapidly converted to albendazole sulfoxide, the active metabolite. Peak plasma levels, sulfoxide: 2-5 hr. t 1/2, terminal, of sulfoxide: 8-12 hr. Further metabolized to other metabolites with excretion through the bile, accounting for a portion of elimination.
Uses: Treatment of parenchymal neurocysticercosis due to Taenia solium. Treatment of cystic hydatid disease of the liver, lung, and peritoneum caused by the larval form of the dog tapeworm Echinococcus granulosus.
Contraindications: Hypersensitivity to benzimidazole compounds.
Special Concerns: Use with caution during lactation. Clients should not become pregnant for at least 1 month following termination of albendazole therapy.
Side Effects: GI: N&V, abdominal pain. CNS: Headache, dizziness, vertigo, increased ICP, meningeal signs. Hematologic: Leukopenia, granulocytopenia, pancytopenia, agranulocytosis, thrombocytopenia (rare). Dermatologic: Reversible alopecia, rash, urticaria. Miscellaneous: Fever, allergic reactions, acute renal failure.
How Supplied: Tablet: 200 mg